Indapta Therapeutics has received FDA Fast Track Designation for its natural killer (NK) cell therapy IDP-023 for patients with multiple myeloma (MM) and non-Hodgkin lymphoma (NHL). The company’s universal, allogeneic NK cell therapy platform is comprised of a potent subset of naturally occurring NK cells called G minus NK (g-NK) cells.